UF Health Jacksonville Is First Site To Test Drug To Prevent Excessive Bleeding

UF Health Jacksonville is the first site in the world to test a new drug designed to prevent excessive bleeding that can occur from taking ticagrelor, a popular blood-thinning medication sold under the brand name Brilinta.

People who are at risk for heart complications and require stents often take blood thinners to reduce the likelihood of experiencing stent clotting, a heart attack or stroke. However, bleeding is a major side effect of the medication. In addition, patients treated with stents frequently require different types of surgery, which also increases the risk of bleeding.

“An issue for many years has been how to optimally manage these patients who may have a bleeding complication as a result of being on Brilinta or who may need to undergo surgery, which further increases the bleeding risk,” said Dr. Dominick Angiolillo, a professor of medicine and director of cardiovascular research at the University of Florida College of Medicine – Jacksonville, who is facilitating the clinical trial. “We’re exploring how well bentracimab, a recently developed reversal drug, can address this significant unmet need.”

Learn more about UF Health Jacksonville Is First Site To Test Drug To Prevent Excessive Bleeding.